PTC Therapeutics/PTCT

$24.69

-1.86%
-
1D1W1MYTD1YMAX

About PTC Therapeutics

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Ticker

PTCT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Matthew Klein

Employees

988

Headquarters

Warren, United States

PTC Therapeutics Metrics

BasicAdvanced
$1.93B
Market cap
-
P/E ratio
-$8.37
EPS
0.70
Beta
-
Dividend rate
$1.93B
0.70026
$59.84
$17.53
914.92K
2.021
1.97
-1.43%
-34.8%
-48.35%
2.055
34.2%
-7.53%
35.05%

What the Analysts think about PTC Therapeutics

Analyst Ratings

Majority rating from 14 analysts.
Hold

Price Targets

Average projection from 11 analysts.
13.04% upside
High $45.00
Low $15.00
$24.69
Current price
$27.91
Average price target

PTC Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-50.71% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$307M
56.23%
Net income
$-155.7M
17.16%
Profit margin
-50.71%
-25.02%

PTC Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 515.71%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.88
-$2.66
-$1.76
-$2.06
-
Expected
-$1.30
-$1.24
-$1.17
$0.50
-$1.25
Surprise
44.78%
113.71%
50.36%
-515.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for PTC Therapeutics stock?

PTC Therapeutics (PTCT) has a market cap of $1.93B as of April 19, 2024.

What is the P/E ratio for PTC Therapeutics stock?

The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 0 as of April 19, 2024.

Does PTC Therapeutics stock pay dividends?

No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of April 19, 2024.

When is the next PTC Therapeutics dividend payment date?

PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.

What is the beta indicator for PTC Therapeutics?

PTC Therapeutics (PTCT) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the PTC Therapeutics stock price target?

The target price for PTC Therapeutics (PTCT) stock is $27.91, which is 13.04% above the current price of $24.69. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell PTC Therapeutics stock

Buy or sell PTC Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing